GUIDED THERAPEUTICS INC (GTHP) stock: key figures, P/E, revenue and dividend

Health Care · United States

Price
0.11 USD
Market cap
10.62 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

GUIDED THERAPEUTICS INC financials

Fiscal year2025
Revenue767,000.00 USD
Gross profit571,000.00 USD
Operating income-2.37 m USD
EBIT-2.58 m USD
Net income-3.20 m USD
Diluted EPS – continuing operations-0.04 USD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About GUIDED THERAPEUTICS INC

Guided Therapeutics, Inc., a medical technology company, researches, develops, tests, manufactures, sells, and distributes medical devices in the United States and internationally. It offers LuViva, an advanced cervical scan non-invasive cervical cancer detection device that provides less invasive and painless alternative to conventional tests for identifying, screening, and detecting cervical cancers and precancers. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is headquartered in Peachtree Corners, Georgia.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.